HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors

Physiological Research

Volumn 63, Issue SUPPL.2, 2014, Pages

  Jochmanova I ^a,b   Zelinka, T ^c   Widimsky Jr J ^c   Pacak, K ^b  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hypoxia inducible factor; Oxygen sensing; Paraganglioma; Pheochromocytoma; Therapy

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADRENAL TUMOR; ANIMAL; GENETICS; HUMAN; METABOLISM; NEUROENDOCRINE TUMOR; PATHOLOGY; PHEOCHROMOCYTOMA; PROGNOSIS; SIGNAL TRANSDUCTION;

ADRENAL GLAND NEOPLASMS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEUROENDOCRINE TUMORS; PHEOCHROMOCYTOMA; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84903774921     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. ARVIDSSON Y, BERGSTROM A, ARVIDSSON L, KRISTIANSSON E, AHLMAN H, NILSSON O Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr Relat Cancer 17: 303-316, 2010.
2. ASTUTI D, RICKETTS CJ, CHOWDHURY R, MCDONOUGH MA, GENTLE D, KIRBY G, SCHLISIO S, KENCHAPPA RS, CARTER BD, KAELIN WG JR, RATCLIFFE PJ, SCHOFIELD CJ, LATIF F, MAHER ER Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer 18: 73-83, 2011.
3. AYALA-RAMIREZ M, FENG L, JOHNSON MM, EJAZ S, HABRA MA, RICH T, BUSAIDY N, COTE GJ, PERRIER N, PHAN A, PATEL S, WAGUESPACK S, JIMENEZ C Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96: 717-725, 2011.
4. BLOUW B, SONG H, TIHAN T, BOSZE J, FERRARA N, GERBER HP, JOHNSON RS, BERGERS G The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4: 133-146, 2003.
5. BROUWERS FM, EISENHOFER G, TAO JJ, KANT JA, ADAMS KT, LINEHAN WM, PACAK K High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91: 4505-4509, 2006.
6. BRUGAROLAS J, LEI K, HURLEY RL, MANNING BD, REILING JH, HAFEN E, WITTERS LA, ELLISEN LW, KAELIN WG JR Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893-2904, 2004.
7. BUFFET A, SMATI S, MANSUY L, MENARA M, LEBRAS M, HEYMANN MF, SIMIAN C, FAVIER J, MURAT A, CARIOU B, GIMENEZ-ROQUEPLO AP Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab 99: E369-E373, 2014.
8. BURNICHON N, VESCOVO L, AMAR L, LIBE R, DE REYNIES A, VENISSE A, JOUANNO E, LAURENDEAU I, PARFAIT B, BERTHERAT J, PLOUIN PF, JEUNEMAITRE X, FAVIER J, GIMENEZ-ROQUEPLO AP Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 20: 3974-3985, 2011.
9. CAPODIMONTI S, TEOFILI L, MARTINI M, CENCI T, IACHININOTO MG, NUZZOLO ER, BIANCHI M, MURDOLO M, LEONE G, LAROCCA LM Von Hippel-Lindau disease and erythrocytosis. J Clin Oncol 30: e137-e139, 2012.
10. CARROLL VA, ASHCROFT M Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270, 2006.
11. CASTRO-VEGA LJ, BUFFET A, DE CUBAS AA, CASCON A, MENARA M, KHALIFA E, AMAR L, AZRIEL S, BOURDEAU I, CHABRE O, CURRAS-FREIXES M, FRANCO-VIDAL V, GUILLAUD-BATAILLE M, SIMIAN C, MORIN A, LETON R, GOMEZ-GRANA A, POLLARD PJ, RUSTIN P, ROBLEDO M, FAVIER J, GIMENEZ-ROQUEPLO AP Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 23: 2440-2446, 2014.
12. COMINO-MENDEZ I, GRACIA-AZNAREZ FJ, SCHIAVI F, LANDA I, LEANDRO-GARCIA LJ, LETON R, HONRADO E, RAMOS-MEDINA R, CARONIA D, PITA G, GOMEZ-GRANA A, DE CUBAS AA, INGLADA-PEREZ L, MALISZEWSKA A, TASCHIN E, BOBISSE S, PICA G, LOLI P, HERNANDEZLAVADO R, DIAZ JA, GOMEZ-MORALES M, GONZALEZ-NEIRA A, RONCADOR G, RODRIGUEZANTONA C, BENITEZ J, MANNELLI M, OPOCHER G, ROBLEDO M, CASCON A Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43: 663-667, 2011.
13. COMINO-MENDEZ I, DE CUBAS AA, BERNAL C, ALVAREZ-ESCOLA C, SANCHEZ-MALO C, RAMIREZTORTOSA CL, PEDRINACI S, RAPIZZI E, ERCOLINO T, BERNINI G, BACCA A, LETON R, PITA G, ALONSO MR, LEANDRO-GARCIA LJ, GOMEZ-GRANA A, INGLADA-PEREZ L, MANCIKOVA V, RODRIGUEZ-ANTONA C, MANNELLI M, ROBLEDO M, CASCON A Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 22: 2169-2176, 2013.
14. CRONA J, DELGADO VERDUGO A, MAHARJAN R, STALBERG P, GRANBERG D, HELLMAN P, BJORKLUND P Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab 98: E1266-E1271, 2013.
15. CRONA J, NORDLING M, MAHARJAN R, GRANBERG D, STALBERG P, HELLMAN P, BJORKLUND P Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours. PLoS One 9: e86756, 2014.
16. DAHIA PL, ROSS KN, WRIGHT ME, HAYASHIDA CY, SANTAGATA S, BARONTINI M, KUNG AL, SANSO G, POWERS JF, TISCHLER AS, HODIN R, HEITRITTER S, MOORE F, DLUHY R, SOSA JA, OCAL IT, BENN DE, MARSH DJ, ROBINSON BG, SCHNEIDER K, GARBER J, ARUM SM, KORBONITS M, GROSSMAN A, PIGNY P, TOLEDO SP, NOSE V, LI C, STILES CD A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1: 72-80, 2005.
17. EISENHOFER G, BORNSTEIN SR, BROUWERS FM, CHEUNG NK, DAHIA PL, DE KRIJGER RR, GIORDANO TJ, GREENE LA, GOLDSTEIN DS, LEHNERT H, MANGER WM, MARIS JM, NEUMANN HP, PACAK K, SHULKIN BL, SMITH DI, TISCHLER AS, YOUNG WF JR Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423-436, 2004a.
18. EISENHOFER G, HUYNH TT, PACAK K, BROUWERS FM, WALTHER MM, LINEHAN WM, MUNSON PJ, MANNELLI M, GOLDSTEIN DS, ELKAHLOUN AG Distinct gene expression profiles in norepinephrineand epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 11: 897-911, 2004b.
19. EISENHOFER G, LENDERS JW, SIEGERT G, BORNSTEIN SR, FRIBERG P, MILOSEVIC D, MANNELLI M, LINEHAN WM, ADAMS K, TIMMERS HJ, PACAK K Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48: 1739-1749, 2012.
20. FAVIER J, BUFFET A, GIMENEZ-ROQUEPLO AP HIF2A mutations in paraganglioma with polycythemia. N Engl J Med 367: 2161; author reply 2161-2162, 2012.
21. FAVIER J, GIMENEZ-ROQUEPLO AP Pheochromocytomas: the (pseudo)-hypoxia hypothesis. Best Pract Res Clin Endocrinol Metab 24: 957-968, 2010.
22. FOSTER KG, FINGAR DC Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077, 2010.
23. GAAL J, BURNICHON N, KORPERSHOEK E, RONCELIN I, BERTHERAT J, PLOUIN PF, DE KRIJGER RR, GIMENEZ-ROQUEPLO AP, DINJENS WN Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95: 1274-1278, 2010.
24. GAZTAMBIDE S, VAZQUEZ F, CASTANO L Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva Endocrinol 38: 17-28, 2013.
25. GIATROMANOLAKI A, SIVRIDIS E, KOUSKOUKIS C, GATTER KC, HARRIS AL, KOUKOURAKIS MI Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13: 493-501, 2003.
26. GIMENEZ-ROQUEPLO AP, DAHIA PL, ROBLEDO M An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44: 328-333, 2012.
27. GIMENEZ-ROQUEPLO AP, FAVIER J, RUSTIN P, MOURAD JJ, PLOUIN PF, CORVOL P, ROTIG A, JEUNEMAITRE X The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 69: 1186-1197, 2001.
28. HEIKKILA M, PASANEN A, KIVIRIKKO KI, MYLLYHARJU J Roles of the human hypoxia-inducible factor (HIF)-3alpha variants in the hypoxia response. Cell Mol Life Sci 68: 3885-3901, 2011.
29. HOCKEL M, VAUPEL P Biological consequences of tumor hypoxia. Semin Oncol 28: 36-41, 2001.
30. HOLMQUIST-MENGELBIER L, FREDLUND E, LOFSTEDT T, NOGUERA R, NAVARRO S, NILSSON H, PIETRAS A, VALLON-CHRISTERSSON J, BORG A, GRADIN K, POELLINGER L, PAHLMAN S Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423, 2006.
31. HRASCAN R, PECINA-SLAUS N, MARTIC TN, COLIC JF, GALL-TROSELJ K, PAVELIC K, KARAPANDZA N Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas. J Neuroendocrinol 20: 1015-1022, 2008.
32. HU CJ, WANG LY, CHODOSH LA, KEITH B, SIMON MC Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374, 2003.
33. JAFRI M, MAHER ER The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 166: 151-158, 2012.
34. JANG MS, PARK JE, LEE JA, PARK SG, MYUNG PK, LEE DH, PARK BC, CHO S Binding and regulation of hypoxia-inducible factor-1 by the inhibitory PAS proteins. Biochem Biophys Res Commun 337: 209-215, 2005.
35. JIANG S, DAHIA PL Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology 152: 2133-2140, 2011.
36. JOGI A, VALLON-CHRISTERSSON J, HOLMQUIST L, AXELSON H, BORG A, PAHLMAN S Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 295: 469-487, 2004.
37. JOHANNESSEN CM, RECZEK EE, JAMES MF, BREMS H, LEGIUS E, CICHOWSKI K The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102: 8573-8578, 2005.
38. JOCHMANOVA I, YANG C, ZHUANG Z, PACAK K Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst 105: 1270-1283, 2013.
39. KAELIN WG JR, RATCLIFFE PJ Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
40. KARASEK D, SHAH U, FRYSAK Z, STRATAKIS CA, PACAK K An update on the genetics of phaeochromocytoma. J Hum Hypertens 27: 141-147, 2012.
41. KEITH B, JOHNSON RS, SIMON MC HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22, 2012.
42. KIM WY, PERERA S, ZHOU B, CARRETERO J, YEH JJ, HEATHCOTE SA, JACKSON AL, NIKOLINAKOS P, OSPINA B, NAUMOV G, BRANDSTETTER KA, WEIGMAN VJ, ZAGHLUL S, HAYES DN, PADERA RF, HEYMACH JV, KUNG AL, SHARPLESS NE, KAELIN WG JR, WONG KK HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119: 2160-2170, 2009.
43. KOH MY, DARNAY BG, POWIS G Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 28: 7081-7095, 2008.
44. KOH MY, LEMOS R JR, LIU X, POWIS G The hypoxia-associated factor switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71: 4015-4027, 2011.
45. KOH MY, POWIS G Passing the baton: the HIF switch. Trends Biochem Sci 37: 364-372, 2012.
46. KONDO K, KIM WY, LECHPAMMER M, KAELIN WG JR Inhibition of HIF2alpha is sufficient to suppress pVHLdefective tumor growth. PLoS Biol 1: E83, 2003.
47. LADROUE C, CARCENAC R, LEPORRIER M, GAD S, LE HELLO C, GALATEAU-SALLE F, FEUNTEUN J, POUYSSEGUR J, RICHARD S, GARDIE B PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 359: 2685-2692, 2008.
48. LAND SC, TEE AR Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282: 20534-20543, 2007.
49. LANDO D, PEET DJ, GORMAN JJ, WHELAN DA, WHITELAW ML, BRUICK RK FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471, 2002.
50. LAU KW, TIAN YM, RAVAL RR, RATCLIFFE PJ, PUGH CW Target gene selectivity of hypoxia-inducible factoralpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer 96: 1284-1292, 2007.
51. LEE S, NAKAMURA E, YANG H, WEI W, LINGGI MS, SAJAN MP, FARESE RV, FREEMAN RS, CARTER BD, KAELIN WG JR, SCHLISIO S Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167, 2005.
52. LIU XW, CAI TY, ZHU H, CAO J, SU Y, HU YZ, HE QJ, YANG B Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy 10: 111-122, 2014.
53. LODISH M Multiple endocrine neoplasia type 2. Front Horm Res 41: 16-29, 2013.
54. LOPEZ-JIMENEZ E, GOMEZ-LOPEZ G, LEANDRO-GARCIA LJ, MUNOZ I, SCHIAVI F, MONTERO-CONDE C, DE CUBAS AA, RAMIRES R, LANDA I, LESKELA S, MALISZEWSKA A, INGLADA-PEREZ L, DE LA VEGA L, RODRIGUEZ-ANTONA C, LETON R, BERNAL C, DE CAMPOS JM, DIEZ-TASCON C, FRAGA MF, BOULLOSA C, PISANO DG, OPOCHER G, ROBLEDO M, CASCON A Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24: 2382-2391, 2010.
55. LORENZO FR, YANG C, NG TANG FUI M, VANKAYALAPATI H, ZHUANG Z, HUYNH T, GROSSMANN M, PACAK K, PRCHAL JT A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 91: 507-512, 2013.
56. MAKINO Y, CAO R, SVENSSON K, BERTILSSON G, ASMAN M, TANAKA H, CAO Y, BERKENSTAM A, POELLINGER L Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554, 2001.
57. MAXWELL PH, PUGH CW, RATCLIFFE PJ Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11: 293-299, 2001.
58. MAZUMDAR J, HICKEY MM, PANT DK, DURHAM AC, SWEET-CORDERO A, VACHANI A, JACKS T, CHODOSH LA, KISSIL JL, SIMON MC, KEITH B HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA 107: 14182-14187, 2010.
59. MELILLO G Hypoxia-inducible factor 1 inhibitors. Methods Enzymol 435: 385-402, 2007a.
60. MELILLO G Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26: 341-352, 2007b.
61. MIMEAULT M, BATRA SK Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17: 30-54, 2013.
62. NEUMANN HPH, BAUSCH B, MCWHINNEY SR, BENDER BU, GIMM O, FRANKE G, SCHIPPER J, KLISCH J, ALTEHOEFER C, ZERRES K, JANUSZEWICZ A, ENG C Germ-line mutations in nonsyndromic pheochromocytoma. New Engl J Med 346: 1459-1466, 2002.
63. NILSSON H, JOGI A, BECKMAN S, HARRIS AL, POELLINGER L, PAHLMAN S HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res 303: 447-456, 2005.
64. PACAK K: Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul 45: 65-90, 2011.
65. PACAK K, EISENHOFER G, AHLMAN H, BORNSTEIN SR, GIMENEZ-ROQUEPLO AP, GROSSMAN AB, KIMURA N, MANNELLI M, MCNICOL AM, TISCHLER AS Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3: 92-102, 2007.
66. PACAK K, JOCHMANOVA I, PRODANOV T, YANG C, MERINO MJ, FOJO T, PRCHAL JT, TISCHLER AS, LECHAN RM, ZHUANG Z New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 31: 1690-1698, 2013.
67. PERCY MJ, FURLOW PW, LUCAS GS, LI X, LAPPIN TR, MCMULLIN MF, LEE FS A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358: 162-168, 2008.
68. PRCHAL JT, GORDEUK VR The HIF2A gene in familial erythrocytosis. N Engl J Med 358: 1966; author reply 1966-1967, 2008.
69. QIN Y, YAO L, KING EE, BUDDAVARAPU K, LENCI RE, CHOCRON ES, LECHLEITER JD, SASS M, ARONIN N, SCHIAVI F, BOARETTO F, OPOCHER G, TOLEDO RA, TOLEDO SP, STILES C, AGUIAR RC, DAHIA PL Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42: 229-233, 2010.
70. RANKIN EB, BIJU MP, LIU Q, UNGER TL, RHA J, JOHNSON RS, SIMON MC, KEITH B, HAASE VH Hypoxiainducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068-1077, 2007.
71. RAVAL RR, LAU KW, TRAN MG, SOWTER HM, MANDRIOTA SJ, LI JL, PUGH CW, MAXWELL PH, HARRIS AL, RATCLIFFE PJ Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686, 2005.
72. RICHTER S, QIN N, PACAK K, EISENHOFER G Role of hypoxia and HIF2alpha in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. Adv Pharmacol 68: 285-317, 2013.
73. ROGERS JL, BAYEH L, SCHEUERMANN TH, LONGGOOD J, KEY J, NAIDOO J, MELITO L, SHOKRI C, FRANTZ DE, BRUICK RK, GARDNER KH, MACMILLAN JB, TAMBAR UK Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor. J Med Chem 56: 1739-1747, 2013.
74. SAHLGREN C, GUSTAFSSON MV, JIN S, POELLINGER L, LENDAHL U Notch signaling mediates hypoxiainduced tumor cell migration and invasion. Proc Natl Acad Sci USA 105: 6392-6397, 2008.
75. SCHEUERMANN TH, LI Q, MA HW, KEY J, ZHANG L, CHEN R, GARCIA JA, NAIDOO J, LONGGOOD J, FRANTZ DE, TAMBAR UK, GARDNER KH, BRUICK RK Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9: 271-279, 2013.
76. SCHLISIO S, KENCHAPPA RS, VREDEVELD LC, GEORGE RE, STEWART R, GREULICH H, SHAHRIARI K, NGUYEN NV, PIGNY P, DAHIA PL, POMEROY SL, MARIS JM, LOOK AT, MEYERSON M, PEEPER DS, CARTER BD, KAELIN WG JR The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22: 884-893, 2008.
77. SCHOFIELD CJ, RATCLIFFE PJ Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004.
78. SEMENZA GL Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
79. SEMENZA GL Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537-547, 2011. Erratum in N Engl J Med 365: 968, 2011.
80. SPEISKY D, DUCES A, BIECHE I, REBOURS V, HAMMEL P, SAUVANET A, RICHARD S, BEDOSSA P, VIDAUD M, MURAT A, NICCOLI P, SCOAZEC JY, RUSZNIEWSKI P, COUVELARD A Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clin Cancer Res 18: 2838-2849, 2012.
81. TAIEB D, YANG C, DELENNE B, ZHUANG Z, BARLIER A, SEBAG F, PACAK K First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab 98: E908-E913, 2013.
82. TAKACOVA M, BULLOVA P, SIMKO V, SKVARKOVA L, POTURNAJOVA M, FEKETEOVA L, BABAL P, KIVELA AJ, KUOPIO T, KOPACEK J, PASTOREK J, PARKKILA S, PASTOREKOVA S Expression pattern of carbonic anhydrase ix in medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway. Am J Pathol 184: 953-965, 2014.
83. TALKS KL, TURLEY H, GATTER KC, MAXWELL PH, PUGH CW, RATCLIFFE PJ, HARRIS AL The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421, 2000.
84. TIAN H, HAMMER RE, MATSUMOTO AM, RUSSELL DW, MCKNIGHT SL The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320-3324, 1998.
85. TOLEDO RA, QIN Y, SRIKANTAN S, MORALES NP, LI Q, DENG Y, KIM SW, PEREIRA MA, TOLEDO SP, SU X, AGUIAR RC, DAHIA PL In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 20: 349-359, 2013.
86. VALENCAK J, KITTLER H, SCHMID K, SCHREIBER M, RADERER M, GONZALEZ-INCHAURRAGA M, BIRNER P, PEHAMBERGER H Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 34: e962-e964, 2009.
87. VICHA A, MUSIL Z, PACAK K Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes 20: 186-191, 2013.
88. WADT K, CHOI J, CHUNG JY, KIILGAARD J, HEEGAARD S, DRZEWIECKI KT, TRENT JM, HEWITT SM, HAYWARD NK, GERDES AM, BROWN KM A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 25: 815-818, 2012.
89. WARNECKE C, ZABOROWSKA Z, KURRECK J, ERDMANN VA, FREI U, WIESENER M, ECKARDT KU Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18: 1462-1464, 2004.
90. WELANDER J, LARSSON C, BACKDAHL M, HARENI N, SIVLER T, BRAUCKHOFF M, SODERKVIST P, GIMM O Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet 21: 5406-5416, 2012.
91. WIESENER MS, JURGENSEN JS, ROSENBERGER C, SCHOLZE CK, HORSTRUP JH, WARNECKE C, MANDRIOTA S, BECHMANN I, FREI UA, PUGH CW, RATCLIFFE PJ, BACHMANN S, MAXWELL PH, ECKARDT KU Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. Faseb J 17: 271-273, 2003.
92. YANG C, SUN MG, MATRO J, HUYNH TT, RAHIMPOUR S, PRCHAL JT, LECHAN R, LONSER R, PACAK K, ZHUANG Z Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 121: 2563-2566, 2013.
93. ZHONG H, DE MARZO AM, LAUGHNER E, LIM M, HILTON DA, ZAGZAG D, BUECHLER P, ISAACS WB, SEMENZA GL, SIMONS JW Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
94. ZHUANG Z, YANG C, LORENZO F, MERINO M, FOJO T, KEBEBEW E, POPOVIC V, STRATAKIS CA, PRCHAL JT, PACAK K Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367: 922-930, 2012.